MDS Nordion

Vancouver, Canada

MDS Nordion

Vancouver, Canada

Time filter

Source Type

This report assesses future trends in molecular imaging equipment revenues as well as growth in the number of unit shipments over the next few years. This will provide value to market participants that design and manufacture molecular imaging equipment. Market participants will also be provided insights on recent industry and technology trends that are shaping the molecular imaging market. Radiopharmaceutical manufacturers will be provided with key insights on the evolving usage trends of workhorse FDG and Tc-99m radiopharmaceuticals and the increasing adoption of new radiopharmaceuticals across new clinical areas. Companies that are in the process of developing software to improve quantitation accuracy, lower dosages, and reduce scan times for both PET and SPECT will be provided with key insights on how the molecular imaging market is growing as well as the factors that are required to facilitate greater adoption of PET and SPECT technologies. Key Topics Covered: 1. Research Methodology 2. Executive Summary-Molecular Imaging 3. Executive Summary-Radiopharmaceuticals 9. Key Products and Participants 10. Latest Trends Among the Big Three Competitors-Philips Healthcare 11. GE Healthcare 12. Siemens Healthineers 13. Companies to Look Out For 14. Other Issues Impacting Growth Of Molecular Imaging 15. Key Technology and Industry Trends 16. Drivers and Restraints-Total Radiopharmaceuticals Market 17. PET Radiopharmaceuticals Segment 18. SPECT Radiopharmaceuticals Segment 19. Key Products and Participants 20. Key Companies to Look Out For 21. Key Industry Trends 22. Role of New Radiopharmaceuticals in Oncology 23. The Last Word 24. Appendix 25. Medicare Hospital Outpatient Prospective Payment System (HOPPS) Companies Mentioned - Advanced Accelerator Applications - Bio-Nucleonics - Blue Earth - Bracco - Cardinal - Eckert & Ziegler Nuclitec - Eli Lilly - GE - IBA Molecular - Jubilant Draximage - Kimberley-clark - Lantheus - MDS Nordion - Mallinckrodt - Mayo Clinic - Molecular Dynamics - Navidea - NeuSoft - PETNET - Pharmalucence - Philips - Piramal - Siemens Healthineers - Spectrum - Toshiba - UltraSPECT For more information about this report visit http://www.researchandmarkets.com/research/5mxv25/analysis_of_the Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/united-states-molecular-imaging-equipment-and-radiopharmaceuticals-market-2017-2023---research-and-markets-300440832.html


Ferreira C.L.,MDS Nordion | Yapp D.T.T.,British Columbia Cancer Agency Research Center | Yapp D.T.T.,University of British Columbia | Crisp S.,MDS Nordion | And 7 more authors.
European Journal of Nuclear Medicine and Molecular Imaging | Year: 2010

Purpose: Improved bifunctional chelates (BFCs) are needed to facilitate efficient 64Cu radiolabeling of monoclonal antibodies (mAbs) under mild conditions and to yield stable, target-specific agents. The utility of two novel BFCs, 1-Oxa-4,7,10-triazacyclododecane-5-S-(4-isothiocyanatobenzyl)-4,7, 10-triacetic acid (p-SCN-Bn-Oxo-DO3A) and 3,6,9,15-tetraazabicyclo[9.3.1] pentadeca-1(15),11,13-triene-4-S-(4-isothiocyanatobenzyl)-3,6,9-triacetic acid (p-SCN-Bn-PCTA), for mAb imaging with 64Cu were compared to the commonly used S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane- tetraacetic acid (p-SCN-Bn-DOTA). Methods: The BFCs were conjugated to trastuzumab, which targets the HER2/neu receptor. 64Cu radiolabeling of the conjugates was optimized. Receptor binding was analyzed using flow cytometry and radioassays. Finally, PET imaging and biodistribution studies were done in mice bearing either HER2/neu-positive or HER2/neu-negative tumors. Results: 64Cu-Oxo-DO3A- and PCTA-trastuzumab were prepared at room temperature in >95% radiochemical yield (RCY) in <30 min, compared to only 88% RCY after 2 h for the preparation of 64Cu-DOTA-trastuzumab under the same conditions. Cell studies confirmed that the immunoreactivity of the mAb was retained for each of the bioconjugates. In vivo studies showed that 64Cu-Oxo-DO3A- and PCTA-trastuzumab had higher uptake than the 64Cu-DOTA-trastuzumab at 24 h in HER2/neu-positive tumors, resulting in higher tumor to background ratios and better tumor images. By 40 h all three of the 64Cu-BFC-trastuzumab conjugates allowed for clear visualization of the HER2/neu-positive tumors but not the negative control tumor. Conclusion: The antibody conjugates of PCTA and Oxo-DO3A were shown to have superior 64Cu radiolabeling efficiency and stability compared to the analogous DOTA conjugate. In addition, 64Cu-PCTA and Oxo-DO3A antibody conjugates may facilitate earlier imaging with greater target to background ratios than the analogous 64Cu-DOTA antibody conjugates. © 2010 Springer-Verlag.


Breton F.,University of Waterloo | Monton M.R.N.,University of Waterloo | Mullett W.M.,MDS Nordion | Pawliszyn J.,University of Waterloo
Analytica Chimica Acta | Year: 2010

We present a novel way to prepare SPME fibers using a silicate entrapment of porous particles, followed by derivatization using classical organosilane chemistry. The fibers provide a good platform for on-fiber derivatization of desired extraction phases while providing porosity necessary for high extractions capacities. The porous network was created using potassium silicate and porous silica particles. Fibers derivatized using n-butyl, n-octyl, n-octadecyl and n-triacontyl groups were shown to extract benzodiazepines successfully. The coatings were determined to have an average thickness of ca. 8μm, as determined by a scanning electron microscope, permitting equilibrium times as fast as 2min. The fibers also showed very good ruggedness towards a vast range of solvents and prolonged use. It was determined that greater extraction efficiencies could be obtained using triacontyl as an extraction phase. The C18 and C30 fibers were also found to provide good linearity (>0.99) for the model analytes over two orders of magnitude, with limits of detection in the sub ngmL-1 levels. C30 fibers were used to establish a correlation between structurally diverse β-blockers and their literature reported LogP values. The C30 fibers provided a good correlation (R2=0.9255) between β-blockers ranging in hydrophobicity from LogPliterature 0.16-4.15 and their respective experimentally determined LogKspme values. © 2010 Elsevier B.V.


Ferreira C.L.,MDS Nordion | Lamsa E.,MDS Nordion | Woods M.,MDS Nordion | Duan Y.,Ottawa Heart Institute | And 6 more authors.
Bioconjugate Chemistry | Year: 2010

Ga radioisotopes, including the generator-produced positron-emitting isotope 68Ga (t 1/2 = 68 min), are of increasing interest for the development of new radiopharmaceuticals. Bifunctional chelates (BFCs) that can be efficiently radiolabeled with Ga to yield complexes with good in vivo stability are needed. To this end, we undertook a systematic comparison of four BFCs containing different chelating moieties: two novel BFCs, p-NO 2-Bn-OxO (l-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid) and p-NO 2-Bn-PCTA (3,6,9,15-tetraazabicyclo [9.3.1]pentadeca-l(1.5),11, 13-triene-3,6,9-triacetic acid), and two more commonly used BFCs, p-NO 2-Bn-DOTA (1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid) and p-NO 2-Bn-NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid). Each BFC was compared with respect to radiolabeling conditions, radiochemical yield, stability, and in vivo clearance properties. p-NO 2-Bn-PCTA, p-NO 2-Bn-OxO, and p-NO 2-Bn-NOTA were all more efficiently radiolabeled with Ga compared to p-NO 2-Bn-DOTA. p-NO 2-Bn-DOTA required longer reaction time, higher concentrations of BFC, or heating to obtain equivalent radiochemical yields. Better stability was observed for p-NO 2-Bn-NOTA and p-NO 2-Bn-PCTA compared to p-NO 2-Bn-DOTA and p-NO 2-Bn-OxO, especially with respect to transmetalation to transferrin. Ga-radiolabled p-NO 2-Bn-OxO was found to be kinetically labile and therefore unstable in vivo. Ga-radiolabeled p-NO 2-Bn-NOTA and p-NO 2-Bn-PCTA were relatively inert, while Ga-radiolabeled p-NO 2-BnDOTA had intermediate stability, losing >20% of Ga in less than one hour when incubated with apo-transferrin. Similar stability differences were seen when incubating at. pH 2. In vivo PET imaging and biodistribution studies in mice showed that 68Ga- radiolabeled p-NO 2-Bn-PCTA, p-NO 2-Bn-NOTA, and p-NO 2-Bn-DOTA all cleared through the kidneys. While there was no statistical difference in the biodistribution results of 68Ga- radiolabeled p-NO 2-Bn-PCTA and p-NO 2-Bn-DOTA, 68Ga-radiolabeled p-NO 2-Bn-NOTA cleared more rapidly from blood and muscle tissue but retained at up to 5 times higher activity in the kidneys. © 2010 American Chemical Society.


Boros E.,University of British Columbia | Boros E.,TRIUMF Laboratory Particle and Nuclear Physics | Ferreira C.L.,MDS Nordion | Cawthray J.F.,University of British Columbia | And 6 more authors.
Journal of the American Chemical Society | Year: 2010

We have investigated novel bifunctional chelate alternatives to the aminocarboxylate macrocycles NOTA (N3O3) or DOTA (N 4O4) for application of radioisotopes of Ga to diagnostic nuclear medicine and have found that the linear N4O2 chelate H2dedpa coordinates 67Ga quantitatively to form [67Ga(dedpa)]+ after 10 min at RT. Concentration-dependent coordination to H2dedpa of either 68Ga or 67Ga showed quantitative conversion to the desired products with ligand concentrations as low as 10-7 M. With 68Ga, specific activities as high as 9.8 mCi nmol-1 were obtained without purification. In a 2 h competition experiment against human apo-transferrin, [67Ga(dedpa)]+ showed no decomposition. Two bifunctional versions of H2dedpa are also described, and these both coordinate to 67Ga at RT within 10 min. Complete syntheses, characterizations, labeling studies, and biodistribution profiles of the 67Ga complexes are presented for the new platform chelates. The stability of these platform chelates is higher than that of DOTA. © 2010 American Chemical Society.


News Article | December 5, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Food Irradiation Market accounted for $145.01 million in 2015 and is expected to reach $194.97 million by 2022 at a CAGR of 4.3% during the forecast period 2015 to 2022. In the present livelihood the people are in need for functional foods which has greater shelf life. Moreover, the demand for managing food-borne illnesses and extension of the shelf life of the food products are favoring the market growth. Whereas factors such as maintaining the quality of raw irradiated meats, developing methods to identify irradiated foods and bringing awareness in public about the integrity of foods are made safer by irradiation, which in turn is an opportunity for the market. Steam Pasteurization and Ultra-High Pressure Technology segment is anticipated to be the largest revenue generating market owing to the rise in number of packaged foods food for daily consumption. However, North America accounted for the largest market and Asia Pacific to be the fastest growing because of more number of population depending on the functional food habits. Some of the key players in food irradiation market include Food Technology Service, Inc, GRAY STAR, Inc., IONISOS SA, MDS Nordion, PHYTOSAN S.A. de, REVISS Services, SADEX Corporation, ScanTech Sciences, Inc., Sterigenics International, Inc. and STERIS Isomedix Services. Technologies Covered: • Food Coating Technology • Fumigation • Ozone Treatment • Steam Pasteurization • Ultra-High Pressure Technology     Processes Covered: • X-Ray Radiation • Electron Beam Radiation  • Gamma Radiation      Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific       • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


News Article | December 9, 2016
Site: marketersmedia.com

According to Stratistics MRC, the Global Food Irradiation Market accounted for $145.01 million in 2015 and is expected to reach $194.97 million by 2022 at a CAGR of 4.3% during the forecast period 2015 to 2022. In the present livelihood the people are in need for functional foods which has greater shelf life. Moreover, the demand for managing food-borne illnesses and extension of the shelf life of the food products are favoring the market growth. Whereas factors such as maintaining the quality of raw irradiated meats, developing methods to identify irradiated foods and bringing awareness in public about the integrity of foods are made safer by irradiation, which in turn is an opportunity for the market. Steam Pasteurization and Ultra-High Pressure Technology segment is anticipated to be the largest revenue generating market owing to the rise in number of packaged foods food for daily consumption. However, North America accounted for the largest market and Asia Pacific to be the fastest growing because of more number of population depending on the functional food habits. Some of the key players in food irradiation market include Food Technology Service, Inc, GRAY STAR, Inc., IONISOS SA, MDS Nordion, PHYTOSAN S.A. de, REVISS Services, SADEX Corporation, ScanTech Sciences, Inc., Sterigenics International, Inc. and STERIS Isomedix Services. Leave a Query @ https://www.wiseguyreports.com/enquiry/649643-food-irradiation-global-market-outlook-2016-2022 Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements For more information, please visit https://www.wiseguyreports.com/sample-request/649643-food-irradiation-global-market-outlook-2016-2022

Loading MDS Nordion collaborators
Loading MDS Nordion collaborators